Skip to content

FOR US HEALTHCARE PROFESSIONALS

How can we help?

NOW FDA-APPROVED

The first and only treatment for adults with moderate-to-severe Chronic Hand Eczema (CHE)1,2

Rapid, powerful efficacy1,3

IN ADULTS WITH MODERATE-TO-SEVERE
CHRONIC HAND ECZEMA (CHE)
SKIN CLEARANCE
ITCH AND PAIN RESULTS
BEFORE AND AFTER PHOTOS
IGA-CHE RESULTS

Significant skin clearance1,3

IGA-CHE treatment success at Week 8, ANZUPGO vs cream vehicle3:
• DELTA 1 (N=325/N=162): 22.8% vs 10.5% (P=0.001)        
• DELTA 2 (N=313/N=159): 32.3% vs 9.4% (P<0.0001)

Primary endpoint

Up to 4x

More patients achieved treatment success† on ANZUPGO vs cream vehicle at Week 16 (DELTA 2)1

Secondary endpoint

as early
as week 4

ANZUPGO showed significantly better results vs cream vehicle3

Trial design

IGA-CHE=Investigator's Global Assessment for Chronic Hand Eczema (a 5-point assessment scale: 4, severe; 3, moderate; 2, mild; 1, almost clear; 0, clear); TS=treatment success.1,4

†Treatment success was defined as achieving clear (IGA-CHE 0) or almost-clear (IGA-CHE 1) skin in addition to a ≥2-point improvement from baseline IGA-CHE score.1

ITCH & PAIN RESULTS

Quick relief from itch and pain1,3,5‡

KEY SECONDARY ENDPOINTS
KEY SECONDARY ENDPOINTS

On ANZUPGO, significantly more patients achieved a ≥4-point reduction in HESD-itch at Weeks 2, 4, 8, and 16, and HESD-pain at Weeks 4, 8, and 16 vs cream vehicle

ITCH (BASELINE MEAN SCORE1: 7.1)

PAIN (BASELINE MEAN SCORE1: 6.7)

‡Itch and pain were assessed using the Hand Eczema Symptom Diary (HESD), a self-reported 11-point rating scale designed to measure the 6 CHE signs and symptoms over the past 24 hours.3

§P<0.05 vs cream vehicle for DELTA 1.5

||P<0.05 vs cream vehicle for DELTA 2.5

Itch and pain data were observed over
16 weeks of treatment with ANZUPGO5,6¶

SECONDARY ENDPOINTS
SECONDARY ENDPOINTS

Change in itch and pain scores vs baseline were observed as early as Day 15,6

Itch data by weeks5

Pain data by weeks5

LIMITATIONS |
Data were reported as observed. No conclusions on safety or efficacy should be made based on these results.
LIMITATIONS

Data were reported as observed. No conclusions on safety or efficacy should be made based on these results.

Itch and pain data were observed
from initial application through Day 66¶

EXPLORATORY ENDPOINTS
EXPLORATORY ENDPOINTS

Change in itch and pain scores vs baseline were observed as early as first dose6

Itch data by day (pooled analysis)

Pain data by day (pooled analysis)

LIMITATIONS |
Change in mean HESD-itch and -pain had weekly prespecified endpoints from baseline through Week 16 in DELTA 1 and 2.
This pooled analysis was not prespecified and not adjusted for multiplicity. Conclusions should be made with caution.
LIMITATIONS

Change in mean HESD-itch and -pain had weekly prespecified endpoints from baseline through Week 16 in DELTA 1 and 2.
This pooled analysis was not prespecified and not adjusted for multiplicity. Conclusions should be made with caution.

Itch and pain were assessed using the Hand Eczema Symptom Diary (HESD), a self-reported 11-point rating scale designed to
measure the 6 CHE signs and symptoms over the past 24 hours.3

Before & After Images

See the difference that ANZUPGO
made in the hands of these patients

GO photos

Demonstrated
Safety Profile

Evaluated in 800+ patients for
both short- and long-term use

GO safety

AS LITTLE AS $0

For eligible patients*

WITH COPAY
SAVINGS →